477 related articles for article (PubMed ID: 26910791)
1. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
2. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
3. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
6. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice.
Li L; Che L; Wang C; Blecha JE; Li X; VanBrocklin HF; Calvisi DF; Puchowicz M; Chen X; Seo Y
Mol Imaging Biol; 2016 Jun; 18(3):360-7. PubMed ID: 26567114
[TBL] [Abstract][Full Text] [Related]
7. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.
Cao D; Song X; Che L; Li X; Pilo MG; Vidili G; Porcu A; Solinas A; Cigliano A; Pes GM; Ribback S; Dombrowski F; Chen X; Li L; Calvisi DF
Liver Int; 2017 Jan; 37(1):80-89. PubMed ID: 27264722
[TBL] [Abstract][Full Text] [Related]
8. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARĪ± pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
[TBL] [Abstract][Full Text] [Related]
10. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
11. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
12. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
13. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
14. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
16. FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma.
Shihadih D; Wang X; Zushin PH; Khodakivskyi P; Park HM; Tso E; Shiblak J; Misic A; Louie SM; Ward C; Hellerstein M; Nomura DK; Goun E; Urigo F; Calvisi DF; Chen X; Stahl A
Mol Cancer Res; 2024 Jun; 22(6):585-595. PubMed ID: 38358323
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
19. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
20. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.
Zhang S; Wang J; Wang H; Fan L; Fan B; Zeng B; Tao J; Li X; Che L; Cigliano A; Ribback S; Dombrowski F; Chen B; Cong W; Wei L; Calvisi DF; Chen X
Am J Pathol; 2018 Apr; 188(4):995-1006. PubMed ID: 29378174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
